ArticleCardiovascular diabetology. Endocrinology reports2025
Prognostic impact of proteinuria in diabetic patients without chronic kidney disease undergoing percutaneous coronary intervention.
Article in Cardiovascular diabetology. Endocrinology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan.World journal of nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) and chronic kidney disease (CKD) are well-established risk factors for adverse outcomes following percutaneous coronary intervention (PCI). However, the combined impact of DM and CKD on prognosis is underexplored, and the role of proteinuria, particularly in non-CKD patients, remains inadequately addressed. This study therefore evaluates the prognostic significance of DM and CKD in post-PCI patients, with a focus on the independent impact of proteinuria.
methodsWe retrospectively analyzed 4,887 patients who underwent PCI between 2000 and 2018, categorizing them into four groups based on DM and CKD status. Cardiovascular mortality was assessed using Kaplan-Meier survival analysis and multivariate Cox proportional hazard analysis. The prognostic impact of proteinuria (≥ 0.3 g/gCr) was evaluated within each subgroup.
resultsPatients with both DM and CKD exhibited the highest cardiovascular mortality risk (hazard ratio [HR] 3.04, 95% confidence interval [CI] 1.82–5.05; p < 0.001). Proteinuria was an independent predictor of cardiovascular mortality, with the strongest association observed in diabetic patients without CKD (HR 6.7, 95% CI 2.7–16.8; p < 0.001).
conclusionsThe coexistence of DM and CKD synergistically elevates cardiovascular mortality risk after PCI. Proteinuria, especially in diabetic patients without CKD, is a potent prognostic marker. Targeting proteinuria may offer a novel therapeutic approach to improve outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.